Cutler Group LP Ambrx Biopharma Inc. Transaction History

Cutler Group LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$9.3 - $16.6 $9,300 - $16,600	1,000 Added 55.56%	2,800 $32,000
Q2 2023 Jul 18, 2023	SELL	$7.66 - $16.46 $9,958 - $21,398	-1,300 Reduced 41.94%	1,800 $29,000
Q1 2023 May 01, 2023	BUY	$1.46 - $12.54 $3,889 - $33,406	2,664 Added 611.01%	3,100 $27,000
Q4 2022 Feb 07, 2023	BUY	$0.41 - $4.54 $178 - $1,979	436 New	436 $0

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.